Celgene Corporation has completed the procedure for the acquisition of Juno Therapeutics, those common stock are no longer listed for trading on the NASDAQ Global Select Market. The deal gave Celgene a leading position into cellular immunotherapy and added novel technology and advanced cellular manufacturing capabilities in areas of serious unmet needs in hematology and oncology. Juno’s potentially best-in-class CD-19 targeted CAR T therapy JCAR017 (lisocabtagene maraleucel; liso-cel) is currently in pivotal trials for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL).

LEAVE A REPLY

Please enter your comment!
Please enter your name here